2004-2005 Lynn University Chamber Orchestra

Concert Dates: Saturday, February 26, 2005 at 7:30 pm Sunday, February 27, 2005 at 4:00 pmhttps://spiral.lynn.edu/conservatory_otherseasonalconcerts/1044/thumbnail.jp

Estudio Exploratorio-descriptivo y cualitativo de las significaciones que los psicólogos/as integrantes de equipos profesionales de atención de menores de edad, en servicios de salud pública de la ciudad de Mar del Plata, otorgan a la interdisciplina

El presente trabajo tiene por finalidad indagar acerca de las significaciones que los psicólogos que trabajan con menores de edad, en los espacios de la salud pública otorgan a la interdisciplina. Para realizar esta tarea, comenzaremos por hacer un relevamiento de información acerca del concep to de interdisciplina. Luego, intentaremos indagar cuales son las concepciones que se desprenden acerca de dicha noción, en aquellos profesionales psicólogos que trabajan con niños y niñas. Para realizar esta investigación, serán seleccionados diferentes organismos de salud de la ciudad, donde se desempeñan psicólogos/as. Se elaborará un instrumento que nos permita el relevamiento de datos para luego arribar a futuras conclusiones. El mismo será una entrevista semiestructurada, con preguntas abiertas y cerradas, administradaspersonalment

γEpithelial Na+ Channel and the Acid-Sensing Ion Channel 1 expression in the urothelium of patients with neurogenic detrusor overactivity

Both Epithelial Na+ Channel (γENaC) and the Acid-Sensing Ion Channel 1 (ASIC1) belong to Degenerin/Epithelial Na+ channel family that represents a new class of cation channels [1]. Increasing evidences show an involvement of these channels in the control of bladder afferent excitability under physiological and pathological conditions [2]; however, data available on their expression in human urothelium are controversial. Pathogenesis of the neurogenic detrusor overactivity (NDO), one of the most severe disabilities reported in patients with spinal cord lesions (SCL), has been attributed to bladder afferent dysfunction. Therefor, the aim of the present study was to investigate the expression of γENaC and ASIC1 in control urothelium and NDO patients. Controls and SCL patients with a clinical diagnosis of NDO underwent to urodynamic measurements and cystoscopy. Cold cup biopsies were processed for immunohistochemistry and western blots. In controls, γENaC and ASIC1 were expressed in the urothelium with different cell distribution and intensity. In NDO patients, both markers showed consistent changes in their cell distribution and intensity. Moreover, a significant correlation between the higher intensity of γENaC expression in urothelium of NDO patients and lower values of bladder compliance was found. In conclusion, the present findings show important changes in the expression of γENaC and ASIC1 in NDO human urothelium. Of note, while the changes in γENaC might impair the mechanosensory function of urothelium, the increase of the ASIC1 might represent an attempt to compensate excess in local sensitivity

Incertidumbres de modelos hidrológicos predictivos - aplicación a modelos intensidad-duración-recurrencia (I-D-T) de lluvia

Las relaciones intensidad de lluvia-duración-Recurrencia (i-d-T) y el patrón de distribución temporal de las lluvias, requeridos para estimar las "Crecientes de proyecto", empleadas para el proyecto de obras de ingeniería civil y planificación del uso del suelo, solo se pueden extraer de extensos registros de alta frecuencia, normalmente fajas pluviográficas, elemento en general no disponible en Argentina. En cambio, es habitual disponer de otro dato de lluvia provisto por pluviómetros: la lámina diaria total. En la provincia de Córdoba, existe información de relaciones i-d-T para siete estaciones pluviográficas, insuficientes para lograr una buena cobertura espacial de toda la Provincia. En este trabajo, se buscará regionalizar las ternas i-d-T para toda la provincia de Córdoba utilizando una técnica de regionalización la cuál contempla el uso de un modelo predictivo e información pluviométrica la cuál se caracteriza por su mayor densidad espacial. A tal fin se espera plasmar la información disponible en mapas digitales (grillas con resolución espacial acorde a los fines de proyecto) los cuales permitan caracterizar el comportamiento estadístico de la variable lluvia máxima diaria, a través de dos parámetros descriptivos como son la media y desvió estándar de los logaritmos de dichas series, incorporando a través de ellos características locales al modelo predictivo. Toda la información procesada y los mapas elaborados serán conformados en un Sistemas de Información Geográfica (SIG). El proceso metodológico empleado se puede resumir en siete actividades principales, a saber: a) selección de las estaciones pluviométricas disponibles en la provincia de Córdoba en base a la longitud de las series de registros, la verificación sobre las series de valores máximos de lluvias diarias de las hipótesis estadísticas básicas (independencia, estacionalidad y homogeneidad) y detección de datos atípicos. b) Determinación de los parámetros provenientes del análisis de estadística inferencial sobre las series de lluvias máximas diarias registradas en los puestos seleccionados y sobre los logaritmos de ellas. c) Ubicación especial de las distintas estaciones pluviométricas y sus parámetros estadísticos, d) Interpolación de la información puntual, generación de mapas de interpolación y análisis tendencial. e) implementación del Modelo predictivo para la regionalización de las curvas i-d-T. f) cuantificación de las incertidumbres provenientes de las distintas fuentes que permitan determinar el intervalo de confianza de los resultados obtenidos, para ello se espera plantear uno o más de los siguientes enfoques metodológicos, estadística clásica (análisis de primer orden), métodos bayeseanos, principio de pareto y/o principio de equifinalidad. g) Análisis y Validación de los resultados.Fil: Catalini, Carlos Gastón. Universidad Católica de Córdoba. Facultad de Ingeniería; ArgentinaFil: García Rodríguez, Carlos Marcelo. Universidad Católica de Córdoba. Facultad de Ingeniería; Argentin

Manual de procedimientos para el cálculo de lluvias de diseño – (escala provincial y nacional)

El diseño hidrológico se define como la evaluación del impacto de los procesos hidrológicos y la estimación de los valores correspondientes a las variables representativas con fines de diseño. Las pautas para establecer un valor de diseño para obras hidráulicas son el costo y la seguridad. Sobredimensionar las obras es antieconómico, en tanto que, si las estructuras se subdimensionan pueden fallar con resultados catastróficos. Los estudios dirigidos a determinar las crecidas de proyecto de diversas estructuras hidráulicas requieren series de datos históricos de caudal, pero esta información en nuestro país es poco frecuente. En esos casos, el análisis se hace sobre las precipitaciones causantes del fenómeno denominadas lluvia de diseño. El equipo responsable de este proyecto tiene una experiencia de investigación y desarrollo de más de 15 años en el tema. Por lo que el objeto de la presente propuesta es plasmar los avances alcanzados sobre las lluvias de diseño en un manual que permita brindar una herramienta técnica (a escala provincial y nacional) a los profesionales dedicados a la planificación, proyecto y construcción de obras hidráulicas.Fil: Catalini, Carlos Gastón. Universidad Católica de Córdoba. Facultad de Ingeniería; ArgentinaFil: García Rodríguez, Carlos Marcelo. Universidad Católica de Córdoba. Facultad de Ingeniería; Argentin

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

PurposeClinical trials have shown a significant increase in pathologic complete response (pCR) with the addition of pertuzumab to neoadjuvant chemotherapy for patients with early-stage HER-2 positive breast cancer. To date, limited studies have examined comparative outcomes of neoadjuvant pertuzumab in real-world setting. The Neopearl study aimed to assess comparative real-life efficacy and safety of neoadjuvant pertuzumab for these patients.MethodsWe conducted a nationwide retrospective analysis involving 17 oncology facilities with a certified multidisciplinary breast cancer treatment committee. We identified patients with HER-2 positive stage II-III breast cancer treated with neoadjuvant chemotherapy based on trastuzumab and taxanes with or without pertuzumab. All patients underwent breast surgery and received a comprehensive cardiologic evaluation at baseline and after neoadjuvant treatment. Patients who received the combination of pertuzumab, trastuzumab, and chemotherapy constituted case cohort (PTCT), whereas those treated with trastuzumab and chemotherapy accounted for control cohort (TCT). The pCR rate and 5-year event free survival (EFS) were the primary outcomes. Secondary end-points were rates of conversion from planned modified radical mastectomy (MRM) to breast conservation surgery (BCS) and cardiotoxicities.ResultsFrom March 2014 to April 2021, we included 271 patients, 134 (49%) and 137 (51%) in TCT and PTCT cohort, respectively. Positive axillary lymph nodes and stage III were more frequent in PTCT cohort. The pCR rate was significantly increased in patients who received pertuzumab (49% vs 62%; OR 1.74, 95%CI 1.04-2.89) and with HER-2 enriched subtypes (16% vs 85%; OR 2.94, 95%CI 1.60-5.41). After a median follow-up of 5 years, the 5-year EFS was significantly prolonged only in patients treated with pertuzumab (81% vs 93%; HR 2.22, 95%CI 1.03-4.79). The same analysis performed on propensity score matched population showed concordant results. On univariate analysis, only patients with positive lymph nodes were found to benefit from pertuzumab for both pCR and 5-year EFS. The rates of conversion from MRM to BCS and cardiologic toxicities did not differ between the cohorts.ConclusionOur findings support previous data on improved outcomes with the addition of pertuzumab to trastuzumab-based neoadjuvant chemotherapy. This benefit seems to be more significant in patients with clinically positive lymph nodes

Colorectal Cancer Stage at Diagnosis Before vs During the COVID-19 Pandemic in Italy

IMPORTANCE Delays in screening programs and the reluctance of patients to seek medical attention because of the outbreak of SARS-CoV-2 could be associated with the risk of more advanced colorectal cancers at diagnosis. OBJECTIVE To evaluate whether the SARS-CoV-2 pandemic was associated with more advanced oncologic stage and change in clinical presentation for patients with colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS This retrospective, multicenter cohort study included all 17 938 adult patients who underwent surgery for colorectal cancer from March 1, 2020, to December 31, 2021 (pandemic period), and from January 1, 2018, to February 29, 2020 (prepandemic period), in 81 participating centers in Italy, including tertiary centers and community hospitals. Follow-up was 30 days from surgery. EXPOSURES Any type of surgical procedure for colorectal cancer, including explorative surgery, palliative procedures, and atypical or segmental resections. MAIN OUTCOMES AND MEASURES The primary outcome was advanced stage of colorectal cancer at diagnosis. Secondary outcomes were distant metastasis, T4 stage, aggressive biology (defined as cancer with at least 1 of the following characteristics: signet ring cells, mucinous tumor, budding, lymphovascular invasion, perineural invasion, and lymphangitis), stenotic lesion, emergency surgery, and palliative surgery. The independent association between the pandemic period and the outcomes was assessed using multivariate random-effects logistic regression, with hospital as the cluster variable. RESULTS A total of 17 938 patients (10 007 men [55.8%]; mean [SD] age, 70.6 [12.2] years) underwent surgery for colorectal cancer: 7796 (43.5%) during the pandemic period and 10 142 (56.5%) during the prepandemic period. Logistic regression indicated that the pandemic period was significantly associated with an increased rate of advanced-stage colorectal cancer (odds ratio [OR], 1.07; 95%CI, 1.01-1.13; P = .03), aggressive biology (OR, 1.32; 95%CI, 1.15-1.53; P < .001), and stenotic lesions (OR, 1.15; 95%CI, 1.01-1.31; P = .03). CONCLUSIONS AND RELEVANCE This cohort study suggests a significant association between the SARS-CoV-2 pandemic and the risk of a more advanced oncologic stage at diagnosis among patients undergoing surgery for colorectal cancer and might indicate a potential reduction of survival for these patients

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline